Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 30:12:876318.
doi: 10.3389/fonc.2022.876318. eCollection 2022.

Editorial: Interaction Between Modern Radiotherapy and Novel Drugs in Prostate Cancer: Future Perspectives

Beatrice Detti  1 , Thomas Zilli  2 , Gianluca Ingrosso  3 , Ivone Ribeiro  4 , Andrea Lancia  5
Affiliations
Editorial

Editorial: Interaction Between Modern Radiotherapy and Novel Drugs in Prostate Cancer: Future Perspectives

Beatrice Detti et al. Front Oncol. .
No abstract available

Keywords: Stereototactic Body Radiation Therapy (SBRT); androgen receptors inhibitors; metastasis-directed therapies (MDT); poly-ADP-ribose polymerase inhibitors (PARP-I); prostate-specific membrane antigen (PSMA) positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Interaction Between Modern Radiotherapy and Novel Drugs in Prostate Cancer: Future Perspectives

References

    1. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. . Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer. N Engl J Med (2018) 378:1408–18. doi: 10.1056/NEJMoa1715546 - DOI - PubMed
    1. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. . Nonmetastatic, Castration-Resistant Prostate Cancer and Survival With Darolutamide. N Engl J Med (2020) 383:1040–9. doi: 10.1056/NEJMoa2001342 - DOI - PubMed
    1. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. . Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med (2020) 382:2197–206. doi: 10.1056/NEJMoa2003892 - DOI - PubMed
    1. Lord CJ, Ashworth A. PARP Inhibitors: Synthetic Lethality in the Clinic. Science (2017) 355:1152–8. doi: 10.1126/science.aam7344 - DOI - PMC - PubMed
    1. Turk AA, Wisinski KB. PARP Inhibitors in Breast Cancer: Bringing Synthetic Lethality to the Bedside. Cancer (2018) 124:2498–506. doi: 10.1002/cncr.31307 - DOI - PMC - PubMed

Publication types